The Cell and Gene Therapy (CGT) session at BIO Asia-Taiwan 2026 brought together leading genetic medicine pioneers, vector bioprocessing engineers, and clinical investigators to evaluate the rapid evolution of advanced genetic medicines. As the biopharmaceutical sector transitions from traditional therapeutic antibodies into targeted genetic medicines, CGT represents the premier clinical frontier for addressing severe monogenic … Industrializing Hope: The Next Frontier in Advanced Genetic Medicines Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.